Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Jun 1.

Published in final edited form as: Drug Alcohol Depend. 2010 Jan 25;109(1-3):20–29. doi: 10.1016/j.drugalcdep.2009.11.023

Survival analysis depicting the proportion of participants retained in each treatment condition (modafinil versus placebo) throughout the 36 study visits (12 weeks) in the total sample, and separately for participants with baseline lower frequency (18 or fewer of the past 30 days) versus higher frequency (more than 18 of the past 30 days) methamphetamine (MA) use and low CBT attendance (0–2 sessions) versus high CBT attendance (3 or more sessions).

Survival analysis depicting the proportion of participants retained in each treatment condition (modafinil versus placebo) throughout the 36 study visits (12 weeks) in the total sample, and separately for participants with baseline lower frequency (18 or fewer of the past 30 days) versus higher frequency (more than 18 of the past 30 days) methamphetamine (MA) use and low CBT attendance (0–2 sessions) versus high CBT attendance (3 or more sessions).